Atlas Venture, the Cambridge, Mass.-based early-stage, biotech-focused venture firm, has for the first time raised an opportunity fund designed to help it support its most promising, maturing portfolio companies.

The $250 million fund, announced by the firm this morning, is pretty well-timed, as these things go. Though the public markets have bounced back a bit today after several stomach-churning drops in late December, there seems to be growing agreement that 2019 could be a much

Read More At Article Source | Article Attribution